Clinical trial · Observational
Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy
Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy
NCT05141279CI-TRIAL-00055340unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this work to evaluate the accuracy of contrast enhanced spectral mamography in predicting the response to NAC and assessment of residual disease in breast cancer patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (5)
- label
- 1
- description
- Stable
- label
- 2
- description
- Partial response
- label
- 3
- description
- Moderate response
- label
- 4
- description
- Excellent response
- label
- 5
- description
- Complete response
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * patient confirmed diagnosed by early breast cancer decided to received neoadjuvant treatment * locally advanced breast cancer * operable metastatic breast cancer Exclusion Criteria: * patient not candidate for NAC * contrast allergy * renal impairment * pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.